Sun, Sep 21, 2014, 10:30 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • johnpapas893 johnpapas893 Jul 7, 2013 2:11 PM Flag


    In 2008, Takeda paid $8.8 billion for Millenium Pharmaceuticals--basically for Velcade. It is true that the MM space was less crowded then and Velcade had received front-line approval. Still, by comparison Onyx's oncology portfolio is much more impressive: Kyprolis (with substantially less peripheral neuropath and very likely superior efficacy relative to Velcade), Nexavar, Stivarga (substantial royalties), Oprozomib, Palbociclib (8% roylaties but a likely blockbuster).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • John, ONXX now trades at 9.9B valuation, 15% more than AMGN offer already. I expect offer at $140-$145 not more. And I'm not convinced that Dr Coles will sell at that price so we could drop back to $100, at least temporarily. I also think that we'll know this way or another in the next 2 weeks...

124.700.00(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.